Diagnostic tests and prognostic indicators

Molecular methods for detection of minimal residual disease following transplantation in lymphoid and plasma cell disorders. Corradini P et al. Methods Mol Biol. 2014;1109:209-37. doi: 10.1007/978-1-4614-9437-9_12. Clinical Contribution of PET/CT in Myeloma: From the Perspective of a Radiologist. Nakamoto Y. Clin Lymphoma Myeloma Leuk. 2014 Feb;14(1):10-1. doi: 10.1016/j.clml.2013.12.005. Epub 2013 Dec 21. Prognostic value of…

Emerging treatments

Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy.Berenson JR et al. Leukemia. 2014 Jan 16. doi: 10.1038/leu.2014.27. [Epub ahead of print].Immunotherapy for multiple myeloma.Rosenblatt J et al. Expert Rev Hematol. 2014 Jan 13. [Epub ahead of print].Phase I study of MLN8237-investigational Aurora A kinase inhibitor-in relapsed/refractory multiple myeloma, Non-Hodgkin…

Related conditions

Autologous Stem Cell Transplantation for POEMS Syndrome. Nakaseko C.Clin Lymphoma Myeloma Leuk. 2014 Feb;14(1):21-3. doi: 10.1016/j.clml.2013.12.009. Epub 2013 Dec 22. Durable responses with autologous hematopoietic SCT in patients with POEMS syndrome. Patel K et al. Bone Marrow Transplant. 2014 Jan 13. doi: 10.1038/bmt.2013.209. [Epub ahead of print]. Can autologous bone marrow transplantation improve systolic function…

Biology and genetics

Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematological Cancers. Garcia PD et al. Clin Cancer Res. 2014 Jan 28. [Epub ahead of print]. Mechanisms and consequences of constitutive NF-κB activation in B-cell lymphoid malignancies. Nagel D et al. Oncogene. 2014 Jan 27. doi: 10.1038/onc.2013.565. [Epub ahead of print]. Cyclin D1 Amplification in Multiple…

Supportive care

Extracorporeal membrane oxygenation in adult patients with hematologic malignancies and severe acute respiratory failure.Wohlfarth P et al. Crit Care. 2014 Jan 20;18(1):R20. [Epub ahead of print].Clearance of Drugs for Multiple Myeloma Therapy During In Vitro High-Cutoff Hemodialysis.Krieter DH et al. Artif Organs. 2014 Jan 7. doi: 10.1111/aor.12248. [Epub ahead of print].Acupuncture for neuropathic pain due…

Complications of myeloma and its treatments

Continuous low-dose cyclophosphamide and prednisone in the treatment of relapsed/refractory multiple myeloma with severe heart failure.Zhou F et al. Leuk Lymphoma. 2014 Jan 28. [Epub ahead of print].Bortezomib just for induction or also for maintenance in myeloma patients with renal impairment?San Miguel JF. Haematologica. 2014 Jan;99(1):5-6. doi: 10.3324/haematol.2013.100982.Management of bone disease in multiple myeloma.Terpos E…

Current treatments

Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival. Palumbo A et al. J Clin Oncol. 2014 Jan 21. [Epub ahead of print]. Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents. Merz M et…

IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide, lenalidomide or bortezomib-containing regimens

This paper, written by an expert panel of the International Myeloma Working Group, examines the impact of novel treatments on stem cell collection in myeloma patients. It summarises the available evidence and makes recommendations to address identified issues.